donanemab

Key facts

Drug.type

mab

Drug.mab_type

mab

Drug.source

zu/o

Drug.target

Amyloid beta

Drug.tradename

Kisunla

Drug.MedlinePlus

a624048

Drug.DailyMedID

Donanemab

Drug.routes_of_administration

Intravenous

Drug.ATC_prefix

N06

Drug.ATC_suffix

DX05

Drug.legal_US

Rx-only

Drug.legal_EU

Rx-only

Drug.CAS_number

1931944-80-7

Drug.DrugBank

DB16647

Drug.UNII

1ADB65P1KK

Drug.KEGG

D11500

Drug.synonyms

LY3002813, donanemab-azbt

Drug.C

6452

via Wikipedia infobox

💊Medication

Generic name

Donanemab-Azbt

Brand names

Kisunla

Route

Intravenous

Type

Human Prescription Drug

Manufacturer

Eli Lilly and Company

Indications: 1 INDICATIONS AND USAGE KISUNLA TM is indicated for the treatment of Alzheimer's disease. Treatment with KISUNLA should be initiated in patients with mild cognitive impairment or mild dementia stage of disease, the population in which treatment was initiated in the clinical trials. KISUNLA is an… (per FDA label)

• PHASE3NOT_YET_RECRUITING
  Donanemab (LY3002813) Trial in Chinese Participants With Cognitively Unimpaired (Preclinical) Alzheimer's DiseaseEli Lilly and Company · NCT07571161
• PHASE2NOT_YET_RECRUITING
  A Study of Donanemab (LY3002813) in Participants With Early Cognitive Decline (TRAILBLAZER-ALZ 7)Eli Lilly and Company · NCT07589595
• PHASE2/PHASE3NOT_YET_RECRUITING
  A Study of Donanemab, RG6289, or the Combination of Donanemab and RG6289 in Presenilin 1 (PSEN1) E280A Mutation Carriers for the Treatment of Autosomal-Dominant Alzheimer's DiseaseBanner Health · NCT06996730
• PHASE1COMPLETED
  A Study of Donanemab (LY3002813) in Healthy Chinese ParticipantsEli Lilly and Company · NCT05533411
• PHASE1COMPLETED
  A Study of Donanemab (LY3002813) in Healthy ParticipantsEli Lilly and Company · NCT05567159
• PHASE3ACTIVE_NOT_RECRUITING
  A Study of Donanemab (LY3002813) in Participants With Early Alzheimer's Disease (TRAILBLAZER-ALZ 2)Eli Lilly and Company · NCT04437511

via ClinicalTrials.gov